

DRUG THERAPY DAY



Wednesday, June 17, 2026

0800-1515

Four Points by Sheraton London, 1150 Wellington Rd.

Presented by the Division of Clinical Pharmacology and Toxicology

Overall Conference Learning Objectives:

By the end of this program, participants will be able to:

1. Review dermatology-related topics and identify key dermatological emergencies and skin drug reactions.
2. Evaluate therapeutic issues relevant to drug treatments for children and pregnant women.
3. Summarize current hypertension management strategies.
4. Assess the safety of therapeutic options for menopausal symptoms and prostate hyperplasia.
5. Examine the toxicity risks associated with vaping.

AGENDA

08:00 – 08:30 Registration, Coffee/Tea and Light Breakfast

08:30 – 08:45 Welcome and Opening Remarks: Dr. Richard Kim

Session 1 – Dermatology Therapeutics

Moderator: Dr. Steven Gryn, Department of Medicine, Division of Clinical Pharmacology and Toxicology

Time	Topic/Speaker
08:45 - 09:15	<p>Skin in Crisis: Recognizing and Managing Dermatologic Emergencies in Primary Care - Dr. Fiona Lovegrove, Adjunct Professor at the Schulich School of Medicine & Dentistry; Lovegrove Dermatology</p> <p><u>Objectives</u></p> <ol style="list-style-type: none"> 1. Identify clinical patterns and red-flag features that distinguish dermatologic emergencies from less urgent skin conditions. 2. Determine when and how to engage dermatology, internal medicine, or emergency services to ensure timely escalation of care. 3. Counsel patients and families clearly about the urgency, treatment plan, and expectations for ongoing care.

09:15 – 09:45	<p>Demystifying Cutaneous Drug Reactions: A Practical Clinical Approach - Dr. Blanca Rosa Del Pozzo-Magana, Department of Pediatrics, Division of Clinical Pharmacology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Describe the clinical significance of cutaneous adverse drug reactions (CADRs). 2. Identify key diagnostic challenges in evaluating suspected CADRs 3. Classify common and severe CADRs based on time of presentation, morphology and underlying pathophysiologic mechanisms.
09:45 – 10:15	<p>Skin Reactions to Natural Remedies and Naturopathic Drugs: Local and Systemic Effects - Dr. Isabel Bustamante, Department of Medicine, Division of Dermatology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Evaluate the safety, efficacy, and regulatory considerations of natural and naturopathic products, 2. Develop strategies to counsel patients effectively about their potential dermatologic risks. 3. Diagnose and manage common dermatologic adverse effects caused by herbal and naturopathic agents. 4. Apply preventive strategies in clinical practice to reduce dermatologic risks associated with these agents.
10:15 – 10:30	<p>Problem Solving with Compounding - Monica Miatello, Pharmacist, Ultimate Care Compounding</p> <p><u>Objectives</u></p> <ol style="list-style-type: none"> 1. Define Non-Sterile Compounding 2. Describe the Application and Benefits of Compounded Products 3. Analyze the Pros and Cons Regarding Drug Plan Coverage and Cost Effectiveness
10:30 – 10:45	Round Table Discussion

10:45 – 11:00 Nutrition Break

Session 2 – Pediatrics – Therapeutic Issues in Drug Treatment for Pregnant Women and Children

Moderator: Dr. Facundo Garcia-Bournissen, Department of Pediatrics, Division of Clinical Pharmacology and Toxicology

Time	Topic/Speaker
11:00 – 11:20	<p>Pediatric Migraine Treatment – Dr. Ana Marissa Lagman-Bartolome, Department of Pediatrics, Division of Pediatric Neurology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Critically appraise the evidence and clinical application of current oral pharmacological treatments for pediatric migraine. 2. Analyze the role of emerging pharmacological therapies in pediatric migraine management.

	3. Summarize recent updates on the use of CGRP-targeted therapies in pediatric migraine treatment.
11:20 - 11:40	<p>Tiny Shots, Big Protection: Pediatric Vaccines - Dr. Alison Lopez, Department of Pediatrics, Division of Pediatric Infectious Disease</p> <p>Objectives:</p> <ol style="list-style-type: none"> 1. Summarize recent updates in pediatric vaccines 2. Discuss common parental concerns and myths surrounding vaccines
11:40 – 12:00	<p>Drugs of Choice in Pregnancy – Dr. Facundo Garcia-Bournissen, Department of Pediatrics, Division of Clinical Pharmacology and Toxicology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Analyze recent controversies related to medication use in pregnancy 2. Evaluate evidence supporting the safety of anti-depressant medications for individual patients during pregnancy 3. Interpret data supporting the safety of acetaminophen and other medications in pregnancy
12:00 – 12:20	Round Table Discussion

12:20 noon – 1:10 Lunch

Session 3 – Keynote Speaker

Moderator: Dr. Richard Kim, Department of Medicine, Chair, Division of Clinical Pharmacology and Toxicology

Time	Topic/Speaker
1:10 - 1:45	<p>Patient Centered Hypertension Management in 2026 - Dr. George Dresser, Department of Medicine, Divisions of General Internal Medicine and Clinical Pharmacology and Toxicology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Describe the changes in hypertension management for patients in 2026. 2. Discuss how the latest guidelines improve patient care in hypertension. 3. Apply strategies to enhance the value of care provided to patients with hypertension.

1:45 – 2:00 Nutrition Break

Session 4 – Therapeutic Update

Moderator: Denise Keller, Department of Pharmacy, Personalized Medicine Pharmacist, London Health Science Centre

Time	Topic/Speaker
2:00 - 2:10	<p>Non-hormonal Menopause Therapy - Dr. Amanda Wiebe, Department of Family Medicine</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Review the algorithm for menopause assessment and management. 2. Describe alternative options for women who cannot or choose not to take menopausal hormone therapy (MHT). 3. Explain the mechanism of action and summarize the evidence behind new Neurokinin Receptor Antagonists for managing vasomotor symptoms
2:10 - 2:20	<p>Women's Health: a focus on urogynecology - Denise Keller, Department of Pharmacy, Personalized Medicine Pharmacist, London Health Science Centre</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Review urinary incontinence in women 2. Compare therapeutic drug options 3. Discuss clinical pearls for drug selection
2:20 - 2:30	<p>Medical Management of BPH: Maximizing treatment effectiveness while minimizing side effects – Dr. Jeffrey Campbell, Department of Surgery, Division of Urology</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Describe common treatment protocols for benign prostatic hyperplasia (BPH) 2. List common side effects of medications used to treat BPH 3. Explain new minimally invasive treatment options for BPH
2:30 – 2:40	<p>Vaping: Toxicity and Health Effects – Dr. Connie Mackenzie, Department of Medicine, Divisions of Respiriology and Clinical Pharmacology and Toxicology; Assistant Director Ontario/Manitoba/Nunavut Poison Centre</p> <p><u>Objectives:</u></p> <ol style="list-style-type: none"> 1. Analyze the toxicity of vaping. 2. Evaluate the respiratory health effects of vaping.
2:40 – 3:00	Round table Discussions

3:00 – 3:15 p.m. **Closing remarks and completion of the program evaluation**

25% of this program is dedicated to participant interaction.

Course Credits

CFPC (Mainpro+ Certified Activity)

This activity meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University for up to 5.00 Mainpro+® Certified Activity credits.

For RCPSC (MOC Section 1)

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of 5.0 hours (credits are automatically calculated).

Each participant should claim only those hours of credit that he/she spent participating in the educational program.

Non-Financial Sponsorship Statement - This program has received no financial support.

Conference Site

Four Points by Sheraton located at 1150 Wellington Rd. South London, Ontario. Parking is available on site (free of charge). Please Park at the rear of the main building.

Registration

To register on-line: https://www.schulich.uwo.ca/clinpharm/about_us/news/2026/drug_therapy_day_2026.html

Early Bird Registration	\$160.00 (before June 1, 2026)
After Early Bird Registration	\$200.00 (before June 8, 2026)
Student (with proof)	\$75.00

NOTE: Credit card payments will be processed through University of Western Ontario Conference Services